Plain-English translation of NCT03326947 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination chemotherapy called TPF (docetaxel, cisplatin, and fluorouracil) given before surgery can help people with advanced oral cavity cancer live longer and healthier. Researchers have found that this medication may work especially well for patients whose cancer cells have low levels of a protein called stathmin. Half of the participants will receive the medication followed by surgery and radiation, while the other half will have surgery and radiation without the medication first.
Doctors want to know if giving this treatment before surgery can help shrink aggressive oral cancers and prevent them from coming back. Earlier research suggested the medication might help certain patients, but more evidence is needed to confirm this.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group receives two cycles of chemotherapy over a few weeks, followed by surgery and radiation treatment. The other group proceeds directly to surgery and radiation without the chemotherapy first. After treatment, you will have regular follow-up visits to check your health and watch for any recurrence of cancer. The study will follow you for 5 years total, with the recruitment period lasting about 2 years.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Shanghai Jiao Tong University School of Medicine
Enrollment target
~60 participants
Started
January 2018
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.